ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia treatment
At ESC 2024, Dr. Erin Michos discussed the success of obicetrapib trials, showing its ability to reduce LDL. Completion of Phase III TANDEM trial enrollment brings NewAmsterdam closer to launching obicetrapib for HeFH/ASCVD. If successful, it could offer a new treatment for high cholesterol, addressing the unmet need for Lp(a) reduction.
Highlighted Terms
Related News
ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia treatment
At ESC 2024, Dr. Erin Michos discussed the success of obicetrapib trials, showing its ability to reduce LDL. Completion of Phase III TANDEM trial enrollment brings NewAmsterdam closer to launching obicetrapib for HeFH/ASCVD. If successful, it could offer a new treatment for high cholesterol, addressing the unmet need for Lp(a) reduction.